Search research articles
Contact Us
Filters
Showing results (911-920 of 1,306) with videos related to
Page
of 131
Sort By:
Journal of Neurology, Neurosurgery, and Psychiatry
|
December 16, 2014
Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT
Stephen D Silberstein, David W Dodick, Sheena K Aurora, et al.
The Lancet. Neurology
|
June 9, 2019
Pathophysiology, prevention, and treatment of medication overuse headache
Hans-Christoph Diener, David Dodick, Stefan Evers, et al.
The Lancet. Neurology
|
February 21, 2023
Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial
Richard B Lipton, Robert Croop, David A Stock, et al.
The Journal of Headache and Pain
|
November 12, 2022
Premonitory symptoms in migraine: a systematic review and meta-analysis of observational studies reporting prevalence or relative frequency
Anna K Eigenbrodt, Rune Häckert Christensen, Håkan Ashina, et al.
European Journal of Neurology
|
November 13, 2023
Responder rates with eptinezumab over 24 weeks in patients with prior preventive migraine treatment failures: post hoc analysis of the DELIVER randomized clinical trial
Messoud Ashina, Richard B Lipton, Jessica Ailani, et al.
Headache
|
October 14, 2024
Feasibility, acceptability, and fidelity of remote-delivered abbreviated mindfulness-based cognitive therapy interventions for patients with migraine and depressive symptoms
Elizabeth K Seng, Jacob Hill, Annie Kate Reeder, et al.
Headache
|
September 26, 2024
Ubrogepant users' real-world experience: Patients on ubrogepant, characteristics and outcomes (UNIVERSE) study
Anand R Shewale, Weijie Poh, Michael L Reed, et al.
European Journal of Neurology
|
March 16, 2026
Long-Term Improvements Following Initial Migraine Response in Eptinezumab-Treated Participants With Migraine for Whom 2-4 Prior Preventive Treatments Have Failed
Jessica Ailani, Messoud Ashina, Susanne F Awad, et al.
Headache
|
February 9, 2022
Reducing the physical, social, and emotional impact of episodic migraine: Results from erenumab STRIVE and ARISE phase III randomized trials
Ariane K Kawata, Mary Kate Ladd, Richard B Lipton, et al.
Neurology. Clinical Practice
|
September 6, 2021
Elective Hospitalizations for Intractable Headache: Outcomes and Response Predictors
Jessica Kiarashi, Yasmin Jion, Brandon Giglio, et al.
Page
of 131
Search research articles
Search
Showing results (911-920 of 1,306) with videos related to
Sort By:
Page
of 131
Journal of Neurology, Neurosurgery, and Psychiatry
|
December 16, 2014
Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT
Stephen D Silberstein, David W Dodick, Sheena K Aurora, et al.
The Lancet. Neurology
|
June 9, 2019
Pathophysiology, prevention, and treatment of medication overuse headache
Hans-Christoph Diener, David Dodick, Stefan Evers, et al.
The Lancet. Neurology
|
February 21, 2023
Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial
Richard B Lipton, Robert Croop, David A Stock, et al.
The Journal of Headache and Pain
|
November 12, 2022
Premonitory symptoms in migraine: a systematic review and meta-analysis of observational studies reporting prevalence or relative frequency
Anna K Eigenbrodt, Rune Häckert Christensen, Håkan Ashina, et al.
European Journal of Neurology
|
November 13, 2023
Responder rates with eptinezumab over 24 weeks in patients with prior preventive migraine treatment failures: post hoc analysis of the DELIVER randomized clinical trial
Messoud Ashina, Richard B Lipton, Jessica Ailani, et al.
Headache
|
October 14, 2024
Feasibility, acceptability, and fidelity of remote-delivered abbreviated mindfulness-based cognitive therapy interventions for patients with migraine and depressive symptoms
Elizabeth K Seng, Jacob Hill, Annie Kate Reeder, et al.
Headache
|
September 26, 2024
Ubrogepant users' real-world experience: Patients on ubrogepant, characteristics and outcomes (UNIVERSE) study
Anand R Shewale, Weijie Poh, Michael L Reed, et al.
European Journal of Neurology
|
March 16, 2026
Long-Term Improvements Following Initial Migraine Response in Eptinezumab-Treated Participants With Migraine for Whom 2-4 Prior Preventive Treatments Have Failed
Jessica Ailani, Messoud Ashina, Susanne F Awad, et al.
Headache
|
February 9, 2022
Reducing the physical, social, and emotional impact of episodic migraine: Results from erenumab STRIVE and ARISE phase III randomized trials
Ariane K Kawata, Mary Kate Ladd, Richard B Lipton, et al.
Neurology. Clinical Practice
|
September 6, 2021
Elective Hospitalizations for Intractable Headache: Outcomes and Response Predictors
Jessica Kiarashi, Yasmin Jion, Brandon Giglio, et al.
Page
of 131